Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.
INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules
Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.
Revitalist Receives Approval from Biomedical Research Alliance of New York Permitting the Company to Perform Human Subjects Clinical Trials
Revitalist obtains regulatory approval for its clinics to host human clinical trials for psychedelics-based therapies.
Why Microdosing Cannot Replace Psychedelic Medicine
Psychedelic medicine is proving it can provide spectacular treatment results for many mental health disorders. Microdosing may also be an important therapy tool. But there's a catch.
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
COMPASS Pathways reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business.
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
Pasiethea Therapeutics plans to offer three new clinics offering both ketamine-based and "repeated transcranial magnetic stmulation" treatments (rTMS).